SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Deferred Revenue of -$1.32 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-03-09
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was -$114.70K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was -$263.14K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$944.58K, a 132.14% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2024 was -$1.32M, a 200.00% decline from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2023 was $1.32M.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$100.00K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2021 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$114.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$114.70K derived: sum of 2 quarters · filed 2026-03-09 | -$377.83K derived: sum of 3 quarters · filed 2026-03-09 | -$1.32M 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$263.14K derived: sum of 2 quarters · filed 2025-11-14 | -$1.21M 10-Q · filed 2025-11-14 | -$1.51M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$263.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.21M 10-Q · filed 2025-08-07 | -$1.51M derived: sum of 3 quarters · filed 2025-08-07 | -$2.78M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$944.58K 10-Q · filed 2025-05-09 | -$1.25M derived: sum of 2 quarters · filed 2025-05-09 | -$2.52M derived: sum of 3 quarters · filed 2025-05-09 | -$2.56M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$305.01K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.57M derived: sum of 2 quarters · filed 2025-03-31 | -$1.62M derived: sum of 3 quarters · filed 2025-03-31 | $1.32M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.31M derived: sum of 2 quarters · filed 2024-11-06 | $1.63M 10-Q · filed 2024-11-06 | $1.63M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$44.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.89M 10-Q · filed 2024-08-08 | $2.89M derived: sum of 3 quarters · filed 2024-08-08 | $2.89M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.94M 10-Q · filed 2024-05-20 | $2.94M derived: sum of 2 quarters · filed 2024-05-20 | $2.94M derived: sum of 3 quarters · filed 2024-05-20 | $2.94M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 derived: sum of 3 quarters · filed 2023-11-13 | -$100.00K 10-K · filed 2023-04-14 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | -$100.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$100.00K 10-Q · filed 2023-08-21 | ||
| 2022-03-31 | -$100.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |